Latest News

Steffen Schmitz-Valckenberg, MD, discusses how optical coherence tomography-based models may enable rapid, noninvasive assessment of functional loss in GA at Angiogenesis 2026.

Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.

The phase 2 EVIAN study (Early Vitrectomy and Intravitreal Antibiotics for Post-Operative Exogenous Endophthalmitis) (NCT 04522661) showed that performing early vitrectomy for acute endophthalmitis can offer better and faster visual outcomes than the current treament of prescribing antibiotics first.

Three cases illustrate treatment switches and extension intervals across retinal vein occlusion, age-related macular degeneration, and diabetic retinopathy.

Arun C. Gulani, MD, introduces the Gulani classification of refractive lens exchange, a 4-type framework for individualizing premium IOL selection and surgical strategy around each eye's visual potential rather than its diagnosis.

Hasenin Al-khersan, MD, of the Retina Group of Florida, shares real-world RCA registry findings showing that pegcetacoplan significantly reduced both photoreceptor and RPE loss in eyes with GA.

Susvimo works in conjunction with the company’s port delivery platform, Contivue, which was specifically engineered for use with Susvimo.

Charles Wykoff, MD, PhD, of Retina Consultants of Texas, discusses 1 year of real-world revakinagene taroretcel experience, covering patient selection, surgical technique, early safety outcomes, and the platform’s potential beyond MacTel.

Physician AI use has more than doubled since 2023—but the next leap in ophthalmology won't come from smarter diagnostic algorithms alone.

A study of YB-101, a potential treatment for both Graves' disease and thyroid eye disease, has begun dosing the first patients. The molecule receive Fast Track Designation from the FDA.

Outlining the benefits of modulating the gut microbiome in diabetes.

Intravitreal injection of 2% hydroxypropylmethylcellulose (HPMC) dispersive viscoelastic (Eyefill HD, Bausch+Lomb) improved vision and restored ocular anatomy in eyes with structural hypotony that had visual potential.

The trial will enroll approximately 111 patients across the US and Europe following positive FDA feedback from a Type D meeting